Niagen Bioscience, Inc. (NASDAQ: NAGE) is a global bioscience company advancing NAD+ science through its Niagen® platform – a NAD+-boosting longevity supplement protected by a 100+ patent estate. Niagen® powers Tru Niagen®, its leading oral supplement brand, and Niagen® Plus, its pharmaceutical-grade intravenous (Niagen IV) and injectable brand, with Niagen IV available at 1,200+ clinics across the U.S.
Demand for Niagen’s portfolio of evidence-based consumer and clinical longevity solutions continues to increase as awareness of the benefits of NAD+ becomes mainstream, supporting the Company’s consistent profitable growth since 2014.
NAD+ is an essential coenzyme present in all living cells and is fundamental to mitochondrial bioenergetics, metabolic homeostasis, and genomic stability. Research shows NAD+ levels decline with age and metabolic stress, correlating with diminished cellular function and physiological resilience.
In 2025, Niagen delivered $129.4 million in net sales (+30% YoY) and 64.3% gross margin (+250 bps YoY), with net income of $17.4 million (+103% YoY) and $13.5 million in operating cash flow, ending the year with $64.8 million in cash and no outstanding borrowings.